An association of patients and their families, since its creation in 1958, the AFM-Telethon has the same objective: overcome the inevitable and cure rare genetic diseases that have long been neglected and ignored by all.
Thanks to the extraordinary popular support of the Telethon for nearly 40 years and driven by the sole interest of patients, the AFM-Telethon has become a major player for the research and development of innovative therapies for rare diseases, thus contributing to the emergence of a genuine medical revolution benefiting as many people as possible.
Today, the AFM-Telethon supports 40 clinical trials involving 33 different diseases (rare diseases of the skin, muscle, eyesight, blood, liver, myocardial infarction, etc.), including 25 in gene therapy, 4 in cell therapy and 14 in pharmacology.
The association grouped three laboratories that are leaders in the fields of gene therapy and cell therapy (Genethon, Institute of Myology, I-Stem) into the Biotherapies Institute, which brings together more than 600 experts from research and development.
Through its Genethon laboratory, it also co-founded YposKesi, an industrial platform entirely dedicated to the production of gene therapy medicines and a European leader in the pharmaceutical production (GMP) of viral vectors.
